Leap Therapeutics Inc
LPTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$31.86M
Close$
$0.20
74.3% downside
Current Fair Value
74.3% downsideOvervalued by 74.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $31.86 Million |
|---|---|
| Enterprise Value | $25.69 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.07 |
| Beta | 0.09 |
| Outstanding Shares | 168,103,535 |
Return
| Return on Equity | -67.45% |
|---|---|
| Return on Assets | -65.13% |
| Return on Invested Capital | -62.24% |
Valuation & Multiples
| P/E Ratio | -3.34 |
|---|---|
| PEG | -0.83 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 122.91 |
| Enterprise Value to EBIT | -0.49 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5326▼ 143.53% |
|---|---|
| Total Calls | 871,500▲ 207.30% |
| Total Puts | 464,200▼ 16.82% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 11.09%▼ 9.73% |
|---|---|
| Total Invested | $6.24M▼ 37.66% |
| Investors Holding | 47▲ 4.00% |
ESG Score
No data